Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension.
D000818:Animals; D001581:Benzothiadiazines; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004232:Diuretics; D003875:Drug Eruptions / Q000209:etiology; D004359:Drug Therapy, Combination; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000188:drug therapy; D007700:Kinetics; D008750:Methyldopa / Q000009:adverse effects / Q000627:therapeutic use; D011224:Prazosin / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology*; D012083:Renin / Q000097:blood; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013997:Time Factors
D001581:Benzothiadiazines; D004232:Diuretics; D011799:Quinazolines; D049993:Sodium Chloride Symporter Inhibitors; D006830:Hydralazine; D008750:Methyldopa; D012083:Renin; D011224:Prazosin